Quest Diagnostics Inc (DGX): who owns it and who trades it
As of Nov 16, 2026, DGX insiders reported 42 open-market sales worth $48.8M and no purchases in the last 12 months, with 98% of the sale value made under pre-set 10b5-1 plans. The largest seller was J. E. Davis (CEO), with $17.1M. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Quest Diagnostics
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DGX
1,102 funds and institutions reported DGX shares worth $22.3B at the end of Q2 2026, about 95% of the company. The largest holder is BlackRock, Inc. with 8.4%.
Funds and institutions (13F) 95%Everyone else 5%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| BlackRock, Inc. | 9.28M | 8.38% | $2B | +1% |
| Vanguard Capital Management LLC | 7.23M | 6.53% | $1.5B | +1% |
| Vanguard Portfolio Management LLC | 6.13M | 5.54% | $1.3B | +1% |
| State Street Corp | 5.52M | 4.98% | $1.2B | +3% |
| T. Rowe Price Associates | 5.44M | 4.92% | $1.2B | -14% |
| Boston Partners | 4.74M | 4.29% | $1B | +18% |
| JPMorgan Chase & Co | 3.52M | 3.18% | $749M | – |
| Geode Capital Management, LLC | 3.14M | 2.83% | $663M | +2% |
| Morgan Stanley | 2.46M | 2.22% | $522M | -1% |
| EdgePoint Investment Group Inc. | 2.25M | 2.03% | $476M | +0% |
| Dimensional Fund Advisors LP | 1.99M | 1.80% | $421M | +2% |
| Bank of America Corp | 1.94M | 1.75% | $410M | +10% |
| Grantham, Mayo, Van Otterloo & Co. LLC | 1.89M | 1.71% | $400M | +0% |
| Wells Fargo & Company | 1.75M | 1.58% | $371M | -1% |
| Davis Selected Advisers | 1.56M | 1.41% | $330M | -4% |
| Victory Capital Management Inc | 1.55M | 1.40% | $329M | -16% |
| Norges Bank | 1.41M | 1.27% | $298M | – |
| FMR LLC (Fidelity) | 1.40M | 1.26% | $296M | +48% |
| Invesco Ltd. | 1.38M | 1.25% | $292M | -16% |
| Northern Trust Corp | 1.13M | 1.02% | $239M | +1% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, DGX insiders reported $0 of open-market purchases and $48.8M of sales. 98% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Michael J Deppe | Vice president | Sale plan | 6,261 | $260.17 | $1.6M | Form 4 |
| Nov 13, 2026 | Michael J Deppe | Vice president | Sale plan | 5,515 | $260.17 | $1.4M | Form 4 |
| Nov 9, 2026 | Patrick Plewman | Vice president | Sale plan | 4,274 | $257.34 | $1.1M | Form 4 |
| Nov 9, 2026 | Patrick Plewman | Vice president | Sale plan | 6,793 | $257.34 | $1.7M | Form 4 |
| Nov 9, 2026 | Patrick Plewman | Vice president | Sale plan | 650 | $257.34 | $167K | Form 4 |
| Nov 3, 2026 | Catherine T. Doherty | Vice president | Sale plan | 3,818 | $245.45 | $937K | Form 4 |
| Nov 3, 2026 | Catherine T. Doherty | Vice president | Sale plan | 5,990 | $246.26 | $1.5M | Form 4 |
| Nov 3, 2026 | Catherine T. Doherty | Vice president | Sale plan | 1,151 | $246.98 | $284K | Form 4 |
| Nov 3, 2026 | Catherine T. Doherty | Vice president | Sale plan | 2,358 | $248.38 | $586K | Form 4 |
| Nov 3, 2026 | Catherine T. Doherty | Vice president | Sale plan | 3,004 | $249.40 | $749K | Form 4 |
| Nov 3, 2026 | Catherine T. Doherty | Vice president | Sale plan | 2,877 | $250.49 | $721K | Form 4 |
| Nov 3, 2026 | Catherine T. Doherty | Vice president | Sale plan | 2,907 | $251.24 | $730K | Form 4 |
| Oct 26, 2026 | Gary M Pfeiffer | Director | Sale plan | 1,203 | $243.00 | $292K | Form 4 |
| Sep 1, 2026 | J. E. Davis | CEO | Sale plan | 10,000 | $242.72 | $2.4M | Form 4 |
| Aug 28, 2026 | Michael E Prevoznik | Vice president | Sale plan | 430 | $244.51 | $105K | Form 4 |
| Aug 28, 2026 | Michael E Prevoznik | Vice president | Sale plan | 6,237 | $243.63 | $1.5M | Form 4 |
| Aug 28, 2026 | Michael E Prevoznik | Vice president | Sale plan | 16,010 | $242.88 | $3.9M | Form 4 |
| Jul 28, 2026 | Mark E Delaney | Vice president | Sale plan | 1,600 | $235.18 | $376K | Form 4 |
| Jun 4, 2026 | Karthik Kuppusamy | Vice president | Sale plan | 8,147 | $200.00 | $1.6M | Form 4 |
| Jun 1, 2026 | J. E. Davis | CEO | Sale plan | 10,000 | $194.14 | $1.9M | Form 4 |
| Mar 5, 2026 | Catherine T. Doherty | Vice president | Sale plan | 5,558 | $206.21 | $1.1M | Form 4 |
| Mar 5, 2026 | Michael E Prevoznik | Vice president | Sale plan | 3,878 | $206.21 | $800K | Form 4 |
| Mar 5, 2026 | Patrick Plewman | Vice president | Sale plan | 2,855 | $206.21 | $589K | Form 4 |
| Mar 4, 2026 | Karthik Kuppusamy | Vice president | Sale | 2,628 | $204.86 | $538K | Form 4 |
| Mar 3, 2026 | Catherine T. Doherty | Vice president | Sale plan | 632 | $207.73 | $131K | Form 4 |
| Mar 3, 2026 | Michael E Prevoznik | Vice president | Sale plan | 526 | $207.73 | $109K | Form 4 |
| Mar 3, 2026 | Patrick Plewman | Vice president | Sale plan | 410 | $207.73 | $85.2K | Form 4 |
| Mar 2, 2026 | J. E. Davis | CEO | Sale plan | 10,000 | $212.52 | $2.1M | Form 4 |
| Feb 19, 2026 | Patrick Plewman | Vice president | Sale plan | 958 | $204.83 | $196K | Form 4 |
| Feb 19, 2026 | Michael E Prevoznik | Vice president | Sale plan | 1,111 | $204.83 | $228K | Form 4 |
| Feb 19, 2026 | Catherine T. Doherty | Vice president | Sale plan | 1,433 | $204.83 | $294K | Form 4 |
| Feb 13, 2026 | Catherine T. Doherty | Vice president | Sale plan | 10,122 | $206.37 | $2.1M | Form 4 |
| Feb 13, 2026 | Catherine T. Doherty | Vice president | Sale plan | 10,573 | $205.21 | $2.2M | Form 4 |
| Feb 13, 2026 | Catherine T. Doherty | Vice president | Sale plan | 351 | $209.10 | $73.4K | Form 4 |
| Feb 13, 2026 | Catherine T. Doherty | Vice president | Sale plan | 1,619 | $208.21 | $337K | Form 4 |
| Feb 13, 2026 | Catherine T. Doherty | Vice president | Sale plan | 3,500 | $207.08 | $725K | Form 4 |
| Feb 10, 2026 | Patrick Plewman | Vice president | Sale plan | 5,662 | $204.00 | $1.2M | Form 4 |
| Nov 25, 2025 | J. E. Davis | CEO | Sale plan | 9,342 | $191.59 | $1.8M | Form 4 |
| Nov 25, 2025 | J. E. Davis | CEO | Sale plan | 4,747 | $192.97 | $916K | Form 4 |
| Nov 25, 2025 | J. E. Davis | CEO | Sale plan | 41,004 | $192.27 | $7.9M | Form 4 |
| Nov 25, 2025 | Vicky B Gregg | Director | Sale | 1,250 | $191.76 | $240K | Form 4 |
| Nov 18, 2025 | Mark E Delaney | Vice president | Sale plan | 7,946 | $187.35 | $1.5M | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| J. E. Davis | CEO and President, Director | – | $17.1M | Sep 1, 2026 |
| Catherine T. Doherty | EVP, Regional Businesses | – | $12.4M | Nov 3, 2026 |
| Michael E Prevoznik | SVP & General Counsel | – | $6.6M | Aug 28, 2026 |
| Patrick Plewman | SVP for Diagnostic Services | – | $5M | Nov 9, 2026 |
| Michael J Deppe | SVP, Corp. Controller & CAO | – | $3.1M | Nov 13, 2026 |
| Karthik Kuppusamy | SVP, Clinical Solutions | – | $2.2M | Jun 4, 2026 |
| Mark E Delaney | SVP & Chief Commercial Officer | – | $1.9M | Jul 28, 2026 |
| Gary M Pfeiffer | Director | – | $292K | Oct 26, 2026 |
| Vicky B Gregg | Director | – | $240K | Nov 25, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DGX short interest
Low short interest. 3.4% of DGX shares are sold short: about 1 share in 29. Over the last 12 reports the number of shares short went up 1%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 3.73M DGX shares were sold short, 3.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.02M shares, buying them all back would take about 3.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 3.73M | 3.39% | +4% | 1.02M | 3.6 |
| Oct 15, 2026 | 3.57M | 3.25% | +5% | 1.06M | 3.4 |
| Sep 30, 2026 | 3.42M | 3.10% | -5% | 1.27M | 2.7 |
| Sep 15, 2026 | 3.60M | 3.26% | +4% | 975,562 | 3.7 |
| Aug 31, 2026 | 3.45M | 3.12% | +4% | 893,699 | 3.9 |
| Aug 14, 2026 | 3.32M | 3.01% | -10% | 711,512 | 4.7 |
| Jul 31, 2026 | 3.68M | 3.34% | +5% | 1.34M | 2.7 |
| Jul 15, 2026 | 3.51M | 3.18% | -6% | 823,847 | 4.3 |
| Jun 30, 2026 | 3.73M | 3.37% | +9% | 971,160 | 3.8 |
| Jun 15, 2026 | 3.42M | 3.09% | -0% | 802,904 | 4.3 |
| May 29, 2026 | 3.43M | 3.10% | -8% | 822,173 | 4.2 |
| May 15, 2026 | 3.72M | 3.36% | +10% | 744,798 | 5.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Members of Congress who traded DGX
Since Nov 17, 2024, 4 members of Congress reported 4 purchases and 5 sales of DGX. The latest was a purchase by Alan Armstrong on Mar 30, 2026, reported Jul 21, 2026.
Purchases 4Sales 5
Reported trades
| Trade date | Member | Type | Amount | Owner | Reported | Source |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
| Mar 27, 2026 | Alan Armstrong (R-OK) | Purchase | $1K–$15K | Self | Jul 21, 2026 | Report |
| Nov 3, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | Dec 11, 2025 | Report |
| Oct 30, 2025 | Julie Johnson (D-TX) | Sale | $1K–$15K | Joint | Aug 5, 2026 | Report |
| Oct 30, 2025 | Julie Johnson (D-TX) | Purchase | $1K–$15K | Joint | Aug 5, 2026 | Report |
| Jul 24, 2025 | Julia Letlow (R-LA) | Sale | $1K–$15K | Self | Jan 13, 2026 | Report |
| Apr 28, 2025 | Julia Letlow (R-LA) | Purchase | $1K–$15K | Self | Jan 13, 2026 | Report |
| Mar 10, 2025 | Carol D. Miller (R-WV) | Sale | $15K–$50K | Spouse | Aug 13, 2026 | Report |
| Mar 10, 2025 | Carol D. Miller (R-WV) | Sale | $1K–$15K | Self | Apr 11, 2025 | Report |
Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work
Quest Diagnostics company events
Quest Diagnostics filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Oct 22, 2026.
- Oct 22, 2026AnnouncementQuest Diagnostics Incorporated learned of unauthorized access to its Quanum LSM system, which certain clients use to place test orders, receive and look up results. Filing
- Oct 22, 2026ResultsReleased financial results. Filing
- Oct 6, 2026LeadershipQuest Diagnostics Incorporated announced that Catherine T. Doherty will retire in July 2027. Filing
- Jul 23, 2026ResultsReleased financial results. Filing
- May 21, 2026VoteReported shareholder vote results. Filing
- May 8, 2026AgreementQuest Diagnostics Incorporated issued $500 million of 5.000% senior notes due 2036. Filing
- May 1, 2026AnnouncementQuest Diagnostics Incorporated issued a press release announcing the pricing of a public offering of $500 million of its 5.000% senior notes due 2036 under the Company’s shelf registration statement. Filing
- Apr 21, 2026ResultsReleased financial results. Filing
- Mar 12, 2026LeadershipThe Board of Directors of Quest Diagnostics Incorporated, after considering the recommendation of the Board's Governance Committee, elected Timothy Wentworth, former chief executive officer of Walgreens Boots Alliance, as a director. Filing
- Feb 10, 2026AnnouncementThe Company issued a press release announcing that the Company's Board of Directors authorized the Company to repurchase an additional $1 billion of the Company's common stock as part of the Company's common stock repurchase program and increased the quarterly dividend from $0.80 to $0.86 per share. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Quest Diagnostics financials
Famous investors that hold DGX
4 of the 50 well-known investors we track reported holding DGX in their latest 13F filing. The largest position is Jeremy Grantham's, worth $450M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jeremy Grantham · GMO | Q3 2026 | 1.93M | $450M | 1.0% | +2% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 431,647 | $101M | 0.1% | +224% |
| Israel Englander · Millennium Management | Q3 2026 | 117,532 | $27.4M | 0.0% | +928% |
| Ray Dalio · Bridgewater Associates | Q3 2026 | 3,548 | $827K | 0.0% | -6% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DGX in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.0% |
| Nov 10, 2026 | STATE STREET CORPORATION | 13G | 5.0% |
Questions about Quest Diagnostics Inc (DGX) stock
Who owns the most DGX stock?
The largest reported owner of Quest Diagnostics Inc (DGX) is BlackRock, Inc., with 8.4% of the company. In total, 1,102 funds and institutions reported holding DGX at the end of Q2 2026, together about 95% of the shares. See the largest owners.
Are DGX insiders buying or selling?
In the last 12 months, DGX insiders reported no open-market purchases and 42 sales worth $48.8M. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in DGX?
As of Oct 30, 2026, 3.73M DGX shares were sold short, 3.4% of the shares outstanding, up 4.5% from the report before. At the average daily volume of 1.02M shares, buying them all back would take about 3.6 trading days (days to cover). See the history.
Have members of Congress traded DGX?
Yes. 4 members of Congress reported 4 purchases and 5 sales of DGX since Nov 17, 2024. The latest was reported on Aug 13, 2026. See the trades.
Which famous investors hold DGX?
4 of the 50 well-known investors we track reported DGX in their latest 13F filing, including Jeremy Grantham, Ken Griffin, Israel Englander. The largest position is worth $450M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.